We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Instem Plc | LSE:INS | London | Ordinary Share | GB00B3TQCK30 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 830.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From May 2019 to May 2024
TIDMINS
RNS Number : 3859H
Instem plc
12 March 2018
Instem plc
("Instem" or the "Company")
Issue of Equity and Total Voting Rights
Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that, following the exercise of vested unapproved share options, 25,771 ordinary shares of 10p each in the Company ("Ordinary Shares") have been issued.
Application will be made to the London Stock Exchange for the admission of the 25,771 new Ordinary Shares to trading on AIM. Admission is expected to take place at 8.00am on 15 March 2018.
Total Voting Rights
Following the issue and allotment of the above New Ordinary Shares, the Company's issued share capital comprises 15,912,431 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Therefore the total number of voting rights in the Company is 15,912,431.
The figure of 15,912,431 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information, please contact:
Instem plc +44 (0) 1785 825 600 Phil Reason, CEO Nigel Goldsmith, CFO N+1 Singer (Nominated Adviser & Broker) +44 (0) 20 7496 3000 Richard Lindley James White Rachel Hayes Walbrook Financial PR Paul Cornelius +44 (0) 20 7933 8000 Sam Allen instem@walbrookpr.com Helen Cresswell
About Instem
Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.
Instem solutions are in use by customers worldwide and enable our clients to bring life enhancing products to market faster.
Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.
Instem supports over 500 clients through offices in the United States, United Kingdom, France, Japan, China and India.
To learn more about Instem solutions and its mission, please visit instem.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOESFFSUEFASEDD
(END) Dow Jones Newswires
March 12, 2018 05:33 ET (09:33 GMT)
1 Year Instem Chart |
1 Month Instem Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
